12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Revlimid lenalidomide: Phase II data

A Phase II trial in 69 previously untreated CLL patients showed that Revlimid plus rituximab led to an overall response rate (ORR) of 95% in patients <65 years of age (n=40), with 20% achieving a complete response (CR). At a median follow-up of 18 months, median PFS was 19 months. In 29 patients >=65 years of age, Revlimid plus rituximab led...

Read the full 284 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >